image
Healthcare - Biotechnology - NASDAQ - US
$ 1.16
-0.855 %
$ 9.21 M
Market Cap
-0.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BCLI stock under the worst case scenario is HIDDEN Compared to the current market price of 1.16 USD, Brainstorm Cell Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BCLI stock under the base case scenario is HIDDEN Compared to the current market price of 1.16 USD, Brainstorm Cell Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one BCLI stock under the best case scenario is HIDDEN Compared to the current market price of 1.16 USD, Brainstorm Cell Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BCLI

image
$2.4$2.4$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
849 K REVENUE
0.00%
0 OPERATING INCOME
100.00%
-11.6 M NET INCOME
32.39%
-9.09 M OPERATING CASH FLOW
55.55%
12 K INVESTING CASH FLOW
-99.45%
7.97 M FINANCING CASH FLOW
-58.02%
0 REVENUE
0.00%
-3.09 M OPERATING INCOME
3.14%
-2.86 M NET INCOME
3.67%
-1.63 M OPERATING CASH FLOW
-55.63%
0 INVESTING CASH FLOW
0.00%
3.09 M FINANCING CASH FLOW
191.68%
Balance Sheet Brainstorm Cell Therapeutics Inc.
image
Current Assets 385 K
Cash & Short-Term Investments 187 K
Receivables 63 K
Other Current Assets 135 K
Non-Current Assets 1.45 M
Long-Term Investments 0
PP&E 1.24 M
Other Non-Current Assets 206 K
10.21 %3.44 %7.37 %67.74 %11.24 %Total Assets$1.8m
Current Liabilities 8.98 M
Accounts Payable 6.08 M
Short-Term Debt 549 K
Other Current Liabilities 2.35 M
Non-Current Liabilities 618 K
Long-Term Debt 171 K
Other Non-Current Liabilities 447 K
63.36 %5.72 %24.48 %4.66 %Total Liabilities$9.6m
EFFICIENCY
Earnings Waterfall Brainstorm Cell Therapeutics Inc.
image
Revenue 849 K
Cost Of Revenue 0
Gross Profit 849 K
Operating Expenses 0
Operating Income 0
Other Expenses 11.6 M
Net Income -11.6 M
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)849k0849k00(12m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
0.00% OPERATING MARGIN
0.00%
1369.02% NET MARGIN
1369.02%
-149.70% ROE
-149.70%
634.44% ROA
634.44%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Brainstorm Cell Therapeutics Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.6 M
Depreciation & Amortization 240 K
Capital Expenditures 0
Stock-Based Compensation 750 K
Change in Working Capital 1.69 M
Others 13 K
Free Cash Flow -9.09 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Brainstorm Cell Therapeutics Inc.
image
BCLI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Brainstorm Cell Therapeutics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
22.1 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
11.3 K USD 1
9-12 MONTHS
7. News
BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® NEW YORK , June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival data from 10 participants in its Expanded Access Program (EAP) for NurOwn® (autologous MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The EAP enrolled 10 participants who had previously completed the Phase 3 clinical trial. prnewswire.com - 3 weeks ago
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials NEW YORK , May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. prnewswire.com - 1 month ago
Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2025 Earnings Call Transcript Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Joyce Lonergan - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Bob Dagher - Executive Vice President & Chief Medical Officer Netta Blondheim-Shraga - Senior Vice President, Research & Development Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Greetings, and welcome to the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK , May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS). prnewswire.com - 1 month ago
BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK , May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. prnewswire.com - 1 month ago
BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 NEW YORK , May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. prnewswire.com - 1 month ago
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 NEW YORK , May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate update, at 8:30 a.m. Eastern Time on Thursday, May 15, 2025. prnewswire.com - 2 months ago
BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit Presentation of biomarker findings from cerebrospinal fluid analyses Workshop on adaptive and decentralized ALS trial design Panel on clinical trial access and the role of patient and caregiver engagement NEW YORK , May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th Annual ALS Drug Development Summit, to take place May 12-14, 2025, in Boston, MA. The company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the NurOwn® development program, contributing to the broader conversation on the future of ALS clinical research. prnewswire.com - 2 months ago
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting New findings highlight impact of UNC13A genotype on treatment response in ALS NEW YORK , April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new pharmacogenomic data for oral presentation of new findings on NurOwn® at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, to take place from May 6 - 10, 2025 in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for amyotrophic lateral sclerosis (ALS) patients treated with NurOwn® (debamestrocel). prnewswire.com - 2 months ago
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS NEW YORK , April 10, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company developing cutting-edge cell therapies for neurodegenerative diseases, today announced the submission of an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) for NurOwn®, the company's autologous mesenchymal stem cell therapy for amyotrophic lateral sclerosis (ALS). This important milestone sets the stage for the initiation of BrainStorm's highly anticipated Phase 3b clinical trial, which has been designed in collaboration with the FDA under a Special Protocol Assessment (SPA). prnewswire.com - 2 months ago
Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2024 Earnings Call Transcript Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Bob Dagher - Executive Vice President & Chief Medical Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Conference Call Participants Jason McCarthy - Maxim Group David Bautz - Zacks Small-Cap Operator Good morning, everyone, and welcome to BrainStorm Cell Therapeutics Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK , March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update. prnewswire.com - 3 months ago
8. Profile Summary

Brainstorm Cell Therapeutics Inc. BCLI

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 9.21 M
Dividend Yield 0.00%
Description Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Contact 1325 Avenue of Americas, New York City, NY, 10019 https://www.brainstorm-cell.com
IPO Date Oct. 7, 2003
Employees 27
Officers Dr. Ibrahim Dagher M.D. Executive Vice President & Chief Medical Officer Ms. Mary Kay Turner Senior Vice President of Patient Advocacy & Government Affairs Dr. Daniel Offen Ph.D. Chief Scientific Advisor Dr. Hartoun Hartounian Ph.D. Executive Vice President & Chief Operating Officer Dr. Netta Blondheim-Shraga Ph.D. Senior Vice President of Research and Development Mr. Chaim Lebovits President & Chief Executive Officer Mr. Uri Yablonka Executive Vice President, Chief Business Officer, Secretary & Director